Stockalyze
Live web search · Adversarial verification · Real citations

Deep stock research, on demand.

Multi-source equity analysis grounded in live data. Five research angles, adversarially verified, with cited sources. Choose how fast you need it.

For informational purposes only. Not investment advice.

Real reports

See what you'll get

Actual Stockalyze reports — real numbers, cited sources, balanced bull-vs-bear. Your own requests look exactly like these.

INTU logo
INTU

Intuit Inc

Example report

Intuit's fiscal Q1 2027 beat estimates, but the outlook behind it got worse. Revenue was $4.354B, up 12% from $3.885B, against roughly $4.31B expected. GAAP diluted EPS was $2.59, up 63%, and non-GAAP EPS was $2.91, up 56% [2][8]. The beat was $0.21 against a $2.70 consensus or $0.45 against $2.46, depending on the benchmark [2][4]. Sources found no tariff refund, asset-sale gain or legal settlement in the quarter. About $30M of refund-transfer revenue moved from Q2 to Q3, which is a timing shift, not a one-time gain [2][8]. Growth was uneven. Global Business Solutions rose 15% to $3.1B, Consumer rose 7% to $958M (including $708M from Credit Karma) and Mailchimp fell 1% to $313M [5]. The stock fell about 9.8% after hours, from a $310.02 close to roughly $279.6. The guidance caused it: Q2 revenue growth of only 6-7% with TurboTax revenue down year over year, FY27 Consumer growth cut to 2-4% and Credit Karma cut to 3-7% [1][4][9]. Full-year revenue guidance is $23.081-$23.365B (8-9% growth), and non-GAAP EPS guidance of $22.88-$23.12 was reaffirmed [10][21]. The case for selling: core consumer and fintech growth is slowing, Mailchimp's roughly $313M a quarter will leave the revenue base once sold [10], the stock fell about 9.4% in two sessions before earnings with no identified catalyst [23], and the chart is weak. The case for holding: earnings per share are still growing and guidance was kept, cash returns are rising, and the multiple has already compressed a lot. On valuation, the shares trade at about 13.5x the FY27 non-GAAP EPS guidance midpoint at the $310 close and about 12x at the ~$280 after-hours price [21]. Cited multiples vary by source. Trailing P/E is 17.66x on StockAnalysis [20] and about 19.4x on WallStreetZen [12]. Forward P/E is 12.70x on StockAnalysis [20] and about 15x according to Wells Fargo, which also cites about 11.5x EV/FCF [12]. These levels are far below the premium the stock carried near its $682.27 52-week high. The 12-month price change is about -52.3%, with a 52-week range of $252.84-$682.27 [11][18]. Without a sourced 5-year multiple series or peer multiples, the comparison with history is only directional [12][21]. Capital returns are a support. Intuit bought back $1.5B of stock in Q1 (+73% YoY) and raised its quarterly dividend 15% to $1.38, an annualized yield of roughly 1.8% [13][17]. The planned Mailchimp sale to Bending Spoons (reported at about $3.68B, closing in early calendar 2027) earmarks the proceeds for extra FY27 buybacks [10][17]. Any gain on the sale will be a one-time item to strip out of later results [10][17]. Free cash flow is cited at about $7.7B, and the balance sheet looks roughly net-debt-neutral, though this is low-confidence aggregator data [24]. Wall Street is split and leaning cautious. S&P Global data on StockAnalysis shows 34 analysts with a consensus 'Buy' (15 Strong Buy, 5 Buy, 12 Hold, 1 Sell, 1 Strong Sell), so about 41% rate the stock Hold or worse [14]. MarketBeat labels the consensus 'Hold' [14]. Average targets run from about $380 to $430 depending on the aggregator: StockAnalysis $408.86 (range $290-$732), ChartMill $418.76, MarketBeat $417.90, WallStreetZen $379.62, Getquin $394.85 and Benzinga $430.24 [6][7]. The targets most recently set by large banks sit much closer to the price. Morgan Stanley has a Hold at $315, Wells Fargo an Equal Weight raised to $330 and Barclays an Overweight at $408 (all November 17-18). Piper Sandler has a Sell at $290, TD Cowen a Hold at $350 and BMO a Buy at $412, and Goldman Sachs has been reported at Sell with a $304 target [15][16]. Stifel and Goldman downgraded the stock around May-June 2026 [6]. The technical setup is bearish. At the $310.02 close the stock sat below its 50-day average (~$317.9) and its 200-day average (~$348-$349), with the 50-day below the 200-day [3]. RSI(14) was 38.59, weak but not yet oversold, and the after-hours drop will likely push it toward 30 [22]. Possible support is the $252.84 52-week low. Resistance sits near $318, $345.56 and $348-$349 [19]. Things to watch next: the Q2 print against the 6-7% guide and any further cuts to Consumer or Credit Karma, Mailchimp closing terms in an 8-K, how fast extra buybacks start, and how analysts revise targets after the guide [4][10][16][17].

Figures as of Nov 20, 2026 · today

24 verified findings 36 cited sources
ANT logo
ANT

Anthropic, PBC

Example report

Anthropic (ANT) begins trading on the Nasdaq Global Select Market on 2026-11-19 with no price history [2]. The IPO priced at $83, above the marketed $70–$78 range, on 980 million Class A shares, raising about $81.3B in what is reportedly the largest IPO on record [3]. Pricing coverage puts the fully diluted value at about $1.5T [4][18]. The book was reportedly almost 7 times oversubscribed [15][17]. Growth is the core of the bull case. Q3 2026 revenue was about $16.96B, up from about $11.6B in Q2, for $33.24B over nine months [5]. That compares with $4.6B for all of 2025 [6], and H1 2026 revenue of $16.3B was about 14 times H1 2025's $1.16B [5][6]. Customers paying over $100K a year rose to 11,900 from 950 a year earlier, and revenue per dollar of compute rose from 0.69 in Q4 2025 to 2.08 in Q2 2026 [15]. The company also produces cash: H1 2026 free cash flow was about $3.45B ($3.93B operating cash flow less $482M capex), and nine-month operating cash flow was about $6.6B [1]. Mid-year cash and short-term investments were $131.7B, before the $81.3B IPO and a separate $26B private placement with AMD, Broadcom, Google, Micron, Microsoft, Nvidia and TSMC Partners [1]. GAAP results need heavy normalization before they mean much. The H1 2026 GAAP net loss of $80.7B includes $72.4B of non-cash fair-value changes on convertible notes, derivatives and SAFEs [11][12]. The nine-month net loss of about $104B includes a $94.32B fair-value charge [13]. These capital-structure items should largely go away once the instruments convert at listing [11]. On operations, Anthropic earned its first operating profit, $974M, in Q2 2026, then swung to a Q3 operating loss [7][13]. Sources disagree on that loss: Yahoo reports $536M [7] and sec-api.io reports about $567M [13]. The company blames a $5B charge for short-term compute commitments and $2B of non-cash donation-matching charges [7]. Excluding them, Q3 would show an operating profit of several billion dollars [7]. A skeptic would answer that compute charges may recur in a compute-heavy business, so the add-back is debatable [7]. The nine-month operating loss was $1.3B, versus $5.2B a year earlier [7]. Fortune reports adjusted H1 operating income of $1.62B, a 10% margin [13]. Valuation is the main tension for anyone weighing whether to hold or sell. At about $1.5T, ANT trades at roughly 22 times annualized Q3 revenue (about $68B) [9][20] and about 46 times annualized H1 revenue [18]. It pays no dividend, and trailing P/E is not meaningful [9]. The private rounds valued it at $183B in September 2025 and $965B in May 2026 [20]. There is no 5-year history or public peer multiple to compare against, and the closest rival, OpenAI, is private [9][20]. The bear case centers on compute obligations, concentration and dilution. The amended S-1 discloses $895.4B of total committed spend: $69.8B due within 12 months and about $447.5B before 2030-12-31 [8]. The original S-1 had listed $657B of compute commitments, $498B of them (76%) noncancelable, implying about $70B a year [14]. Nearly a quarter of revenue comes from two customers [21]. Risk factors cite a February 2026 federal order to stop using Anthropic's models and June 2026 export restrictions that took two models offline [21]. The board can issue an additional 2% of shares to the Anthropic Public Benefit Fund each time the stock rises 50% above a benchmark [15]. No bank has published a rating or price target [16][19]. Goldman Sachs and Morgan Stanley lead a 22-bank syndicate with J.P. Morgan next [16][19], and syndicate coverage would typically start after the quiet period, around mid-December 2026; that date is an inference, not a reported fact [16]. Technically, moving averages, RSI and support/resistance cannot yet be calculated [2]. The $83 offer price is the only reference level, a possible support if the stock holds above it or resistance if it breaks below [17]. Near-term catalysts are the opening trade, initiation of coverage once the quiet period ends [16], the first public quarterly report, and lock-up expiry, whose terms were not found [21]. The evidence supports both readings: exceptional growth and cash generation on one side, and a premium multiple, large fixed compute commitments and a recent swing back to an operating loss on the other.

Figures as of Nov 19, 2026 · yesterday

21 verified findings 30 cited sources
SLS logo
SLS

Sellas Life Sciences Group Inc

Example report

SELLAS (SLS) is a pre-revenue biotech whose valuation was reset by one binary event. On November 17, 2026 the stock closed at $19.15, up 156.36% in one session from about $7.47. The move followed the company's announcement of positive topline Phase 3 REGAL data for galinpepimut-S (GPS) in AML, which it described as a statistically significant and clinically meaningful improvement in overall survival [9]. The readout came after a volatile run-up. Shares fell 14.71% to $10.38 on October 28, when the trial reached its 80th event, the trigger for the final analysis [1][14]. That event came about 10 months later than planned, which TIKR said could reflect either a GPS benefit or a stronger-than-assumed control arm [8]. The stock then drifted to $8.55–$9.14 in early November and to $7.47 by November 16 [1][14]. Fundamentals are thin. There was no Q3 2026 revenue. The net loss was $10.1M ($0.05/share), versus $6.8M a year earlier. R&D rose to $7.0M from $4.2M, partly on BLA preparation, and G&A rose to $4.3M from $2.9M, mainly from non-cash stock-based compensation. The release identifies no one-time items to normalize [3][7][13]. The balance sheet is clean but small relative to the valuation: $134.7M of cash, no debt and about $9.3M of liabilities at September 30 [4]. At about $3.90B of market cap and about $3.77B of enterprise value [22], P/E and EV/EBITDA are not meaningful. Price-to-book is roughly 30x [15]. Market cap sits far above the company's own 5-year history, which ranges from $34.0M at end-2023 to $537.0M at end-2025 [16]. No peer multiples were verified, so no peer comparison is made [16][21]. The constructive case starts with the trial result itself: a statistically significant overall-survival result in a pivotal trial, as the company describes it [9]. An FDA filing is targeted for 1H 2027, and a second asset, SLS009 (tambiciclib), adds further catalysts. Its newly diagnosed AML Phase 2 data are due in Q4 2026 and relapsed/refractory data will be presented at ASH on December 12–15, 2026. Earlier SLS009 data showed a 54% response rate in monocytic AML and 57% in TP53-mutated AML [8][21]. Sell-side targets are mostly above the current price. Maxim raised its target to $40 from $30 on November 17 and kept its Buy rating [18]. Finviz shows 4 Buy ratings and a $37.50 average target [21]. The pre-readout Maxim/Alliance average of $32.50 was about 70% above the $19.15 close [17]. The cautionary case starts with dilution and how extended the stock is. A proposed $150.0M public offering, announced at 4:01 PM ET on November 17, pushed shares to about $17.07–$17.10 after hours, down about 10.7% [10][22]. That comes on top of 33% share-count growth year to date, to 203.5M shares [7]. TIKR had warned that a win could require equity funding for a BLA and launch [8]. On technicals, RSI(14) is about 76.6–76.7, overbought [2]. The stock trades about 74% above its 50-day average (~$11.01) and about 116% above its 200-day average (~$8.88) [11]. Returns are about +1,258% over 12 months and about +408% year to date [20]. Short interest is 28.34% of float [21]. Derived levels, not published studies, put resistance near the new $24.89 52-week high. Possible support sits at the prior $15.88 high, then ~$11.01, then ~$7.47 [12]. Analyst coverage is thin and comes only from small-cap brokers. No major bank coverage was found [19]. Aggregator consensus figures conflict, ranging from a stale $6.50 to $40 [6][23][24]. Forward risks include the full data details, the FDA review, how the offering is priced, commercialization costs and the SLS009 readouts [8][10][21].

Figures as of Nov 18, 2026 · 2 days ago

24 verified findings 19 cited sources
INTC logo
INTC

Intel Corp

Example report

Intel's Q3 2026 results were mixed once one-time items are normalized. Revenue rose 21% year over year to $16.51B from $13.65B. Data Center and AI drove the growth, up 78% to $7.3B, while Client Computing and Physical AI fell 5% to $8.1B [2][8]. Non-GAAP EPS was $0.52, up from $0.23 and above Intel's own $0.38 guidance, though revenue came in slightly below the $16.56B consensus MarketBeat cites [8]. GAAP EPS fell to $0.60 from $0.90, but that comparison is distorted by one-time items on both sides. The prior-year quarter included a $5,452M divestiture gain, mostly from Altera. Q3 2026 GAAP results were lifted by an Escrowed Shares mark-to-market gain and $330M of net equity-investment gains, which is why GAAP EPS was above non-GAAP [13][18]. Non-GAAP EPS of $0.52 is the better measure of operating results. Over nine months, a $12,614M Escrowed Shares loss and $3,969M of restructuring produced an $11,609M net loss [13]. The outlook is the main problem: Q4 guidance calls for $15.0B to $16.0B of revenue, a 38.0% non-GAAP gross margin (down from 44.1%) and $0.25 of non-GAAP EPS (down from $0.52) [9]. The balance sheet is a support. At quarter end Intel held about $54.0B of cash and investments against about $50.1B of debt, a small net cash position. Q3 operating cash flow was $5.08B, capex $4.22B and adjusted free cash flow $1.64B. However, shares outstanding rose to 5,310M from 4,994M after a $22.6B net equity offering, which dilutes per-share figures [5]. At $55.47 (market cap about $294.8B, EV about $290.6B), trailing P/E is not meaningful because trailing earnings are negative. Forward P/E is 39.85x, P/B 2.56x, P/S 4.92x and EV/EBITDA 15.18x [3]. Against AMD, Intel trades at a slight premium on forward P/E (AMD 33.50x) but at a deep discount on EV/EBITDA (AMD 73.63x), P/B (12.09x) and P/S (18.20x). AMD's TTM free cash flow of $7.06B is also well above Intel's $3.77B [4]. Against its own history, EV/EBITDA is close to FY2025's 15.68x but well above FY2021-FY2022 (6.27x-7.37x). P/B is the highest since at least FY2021, partly because of the equity raise. Forward P/E is below FY2025's 85.44x but well above FY2021-FY2022 (14.22x-18.19x) [21]. Intel pays no dividend [14]. The Wall Street view has moved to cautious. The consensus is Hold: of 49 analysts, 12 rate it Strong Buy, 2 Buy, 34 Hold, 0 Sell and 1 Strong Sell, and other aggregators also show Hold [1]. Ratings and targets were cut widely after Q3. Bank of America downgraded to Neutral and cut its target from $145 to $100, then to $80 [15]. Citi kept its Buy rating but cut its target from $130 to $100 [7]. Barclays and RBC both rate Intel Hold with $75 targets [7]. Roth downgraded to Neutral with a cut from $120 to $70, Freedom Broker moved to Hold at $90, and Susquehanna cut to $105 and later reportedly to $75 [16]. The average target of $90.65 (median $86, range $63-$160) sits well above the price, and the stock is about 12% below even the lowest target. This suggests many targets have not caught up with the sell-off [6]. The cautious case rests on several points: the sharp Q4 margin and EPS step-down [9], a reported two-week Kiryat Gat fab shutdown estimated to cost about $300M of Q4 revenue and about 200bp of gross margin, management's expectation of double-digit PC market contraction through mid-2027, a new securities class action naming the CEO and CFO [20], share dilution [5], and a forward P/E above AMD's [4]. The more patient case points to strong Data Center and AI growth [2], net cash [5], EV/EBITDA far below AMD's [4], and price targets that are still above the price even after the cuts [6][7][15]. Technically, the stock is in a clear downtrend. The day after earnings it reportedly fell about 28.6% to roughly $65.76, described as its worst day since 1974, and it kept falling to $55.47 by Nov 16 [10]. As of Nov 13 it was down 33.60% over one month [17]. The price is far below the 50-day moving average ($94.17) and the 200-day ($87.44). The 14-day RSI is 29.86 and the 5-year beta is 2.43 [19]. Other aggregators put RSI between about 28.8 and 32.42, and MACD (12,26,9) is at -0.260, a sell signal [12]. TipRanks' moving-average tally is 11 Bearish to 1 Bullish [22]. Support is cited in the $52.25 to $54.00 zone [23]. The 52-week range is $32.89 to $142.35, and the stock is still up roughly 47.6% to 56% over a year, depending on the source [11][19]. Key forward risks are delivery against the weak Q4 guide [9], the fab-outage, PC-demand and litigation headwinds [20], and high volatility [19]. Possible catalysts are continued Data Center and AI momentum [2], a reset of analyst targets toward the current price [6], and the oversold readings that Investtech notes can come before a technical rebound [12]. Taken together, the evidence shows real revenue growth and a solid balance sheet set against a sharp margin reset and weak near-term sentiment. Readers should weigh these themselves; this report makes no recommendation.

Figures as of Nov 17, 2026 · 3 days ago

23 verified findings 34 cited sources
ASML logo
ASML

ASML Holding

Example report

Fundamentally, ASML's latest quarter was strong, but the headline overstates it. Q3 2026 net sales were €11,662 million, up from €9,326 million in Q2. Gross margin was 57.5%, net income €4,960 million and basic EPS €12.95, on 113 new and 8 used lithography systems and €3,289 million of Installed Base Management sales [1]. Management guided Q4 net sales to €14.2–15.2 billion at about 57% gross margin and full-year 2026 to €44–45 billion at about 56%. The CEO said planned 2027–2028 supply 'will not fully meet the demand of our customers', and ASML plans to raise low-NA EUV and DUV immersion capacity by 30% in 2027 [2]. A secondary source could not match the Q4 guide to the release [19], but the primary 6-K contains it [2]. The beat needs normalizing. Q3 net income included a gain of roughly €500 million tied to ASML's Mistral AI stake, about 10% of net income [21]. Operating income was about €5.2 billion, so the jump in basic EPS from €7.59 in Q2 to €12.95 in Q3 likely overstates core earnings growth [15]. The balance sheet is net cash. Trailing free cash flow was $23.34 billion against $2.24 billion of total debt. Cash and short-term investments were €12,735 million at quarter-end, after about €4.1 billion of Q3 buybacks [18]. An interim dividend of €1.88 was paid on November 4 (trailing yield about 0.53%) [8]. ASML does not report quarterly bookings, so customer interest in 2029–2030 orders is not firm backlog [2][19]. Valuation and the Wall Street view. At the $1,495.16 close on November 13, ASML traded at 38.77x trailing and 23.44x forward earnings, 29.99x EV/EBITDA and 22.47x book, with a market cap of $564.94 billion [16]. It trades at a premium to Applied Materials on every multiple compared: 29.36x trailing, 19.31x forward, 24.43x EV/EBITDA and 11.25x book, with similar dividend yields (0.53% vs 0.57%) [17]. Against its own history, the trailing P/E and EV/EBITDA sit at the top of the FY2022–FY2025 range (34.3–37.0x and 27.0–28.8x) but below the FY2021 peak of 48.8x and 41.0x, while P/B is above FY2023–FY2025 levels of 14.4–20.0x [22]. MarketScreener's estimates put the P/E at 32.1x for 2026E and 23.5x for 2027E, but that page may be stale [16]. The sell-side remains constructive. MarketBeat shows a 'Moderate Buy' consensus across 24 ratings (2 Strong Buy, 17 Buy, 2 Hold, 3 Sell) with a $2,204.71 average target [3]. That is about 44% above the November 11 mid-day price of $1,534.42 [9]. StockAnalysis puts the average near $2,138, and target lows run $1,415–$1,450 [14]. Named bank targets include Bernstein at $2,623, Wells Fargo at $2,500, JPMorgan at $2,350 (cut from $2,400 on October 15), and RBC and Argus at $2,100 each [10]. Activity in the last 90 days was mostly reiterations plus JPMorgan's $50 trim, with no new rating changes found from Goldman Sachs, Morgan Stanley, BofA or Barclays [11]. A large gap between price and target usually means analysts have not yet caught up with a falling price, not that upside is confirmed [9]. Technical posture and the balanced case. The stock's near-term trend is weak. It sits about 25% below its 52-week high of $1,999.96, though it is up 44.14% over 52 weeks from a low of $946.11 [5]. The price is below both the 50-day average (about $1,660) and the 200-day (about $1,602). The 50-day is still above the 200-day, so the long-term structure holds for now while the near-term trend has broken down [6][4]. The shares fell about 13.6% over 30 days into late October [7]. They dropped 6.67% on November 5 on export-control worries, customer capex caution and higher bond yields, then rose 6.12% on November 9 in an AI rally [7]. RSI(14) has recovered to about 42 from oversold readings of about 27–29 around November 4–5 [12]. Near-term support is around $1,355. Resistance sits at the 200-day and 50-day averages (about $1,600 and $1,660) and at the roughly $2,000 52-week high [13]. The case for caution: a premium multiple against both its peer and its own recent history [17][22], a broken short-term trend [6], a one-time gain inflating Q3 earnings [21], and risks from export controls, tariffs and the gap between stated demand and firm orders [23][7]. The case for patience: confirmed Q4 and full-year guidance, a supply-constrained outlook for 2027–28 with planned capacity growth [2], strong cash generation and buybacks [18], a forward P/E well below the trailing one [16], and catalysts named in the coverage, including AI-driven memory and logic spending and High-NA EUV adoption [23].

Figures as of Nov 16, 2026 · 4 days ago

23 verified findings 32 cited sources
SPCX logo
SPCX

Space Exploration Technologies Corp

Example report

Fundamentals and valuation: SPCX has posted very fast growth, but its profits are still thin when one-time items are taken out, and its valuation is high. Q3 2026 revenue was reported at $14.58B, up 161% year over year, against a $12.59B consensus. EPS was $0.35 against expectations of $0.10-$0.11 [4][13]. This followed a Q2 with $7.81B of revenue and a $541M net loss [4]. The headline Q3 net income of $4.4B needs adjusting. About $2.3B of it came from non-operating and tax items: $0.9B of interest income, $1.0B of other income and a $0.4B tax benefit. Operating income of $2.8B (a 19.1% margin) is the cleaner measure, so roughly half of reported profit did not come from operations [18]. On a trailing basis, net margin is still negative (-8.6%), so P/E is not meaningful. The shares trade at about 59x TTM revenue of $32.04B and an estimated ~133x EV/EBITDA [17], at a market cap of about $1.89T [11][12]. Other snapshots put the multiple at about 63x trailing sales in late August [4] and about 45x estimated 2026 sales in July [11]. Cash flow is the central tension. TTM free cash flow was about -$39.2B on $55.0B of capex, $19.6B of it in Q3 alone. That is cushioned by about $89.9B of cash and securities, or about $51.0B of net cash [14]. Looking ahead, Morgan Stanley does not expect positive FCF before 2035 as capex rises toward $300B a year by 2031, and Goldman estimates about $270B of debt will need to be raised over 2026-2030 [15]. Reported guidance of $100B annualized revenue by end-2026 and $33-37B in Q1 2027 [21] would be a major catalyst if met, but it is a large execution step up from Q3 and has only low-confidence sourcing. The Wall Street view: sell-side sentiment is clearly positive but the targets are very far apart. The S&P Global panel of 40 analysts shows 24 Strong Buy, 8 Buy, 6 Hold, 0 Sell and 2 Strong Sell [9]. The average target is $256.41 and the median $245, implying about 84% and 76% upside, within a range of $70 to $800 [2]. Recent actions are mostly reiterations rather than upgrades: Deutsche Bank at $250, Stifel at $190, and Bank of America kept its Buy without a published target [10]. Goldman raised its target to $230 from $205 [3]. Post-Q3 reports also have TD Cowen at $224 and Morgan Stanley at $300, and say JPMorgan raised to $500 from $240 [8]. The JPMorgan figure itself is unconfirmed [3]. The bearish minority includes Phillip Securities at Sell/$75 (about 46% below the price) and DZ Bank's August cut to Sell [16]. The tension is that the stock closed at $139.11 on November 13. That is only about 3.0% above the $135 IPO price and about 38% below the $225.64 all-time high [1]. It is also roughly flat against the late-August close of $137.95, even though targets were raised [5]. The market has not adopted the sell-side's optimism. Technical posture and forward risks: the price is neutral to weak, and share supply weighs heavily. SPCX sits just above its 50-day SMA ($137.80) and just below its 50-day EMA ($139.93). It is about 6% below a 200-period SMA of $147.34, with RSI(14) at 46.1, and Investing.com's moving-average summary reads 'Strong Sell' [19]. The $135 IPO price has acted as a pivot. Shares dipped to about $123.62 on November 5 and then recovered to $139-$142 [6]. Resistance is near $171.92 (the October 6 high) and $225.64, and support is at the $104.83 52-week low [6]. The price is also down from $147.49 on October 23 [12]. The main near-term event is the December 8 lockup expiry of up to about 797.6M shares (over $110B), following earlier tranches of 911.5M, 319M and up to 1.3B shares [7]. Option-implied volatility near 59% compares with about 69% realized [11], and beta is 3.18 [12]. A political catalyst also hangs over the stock. The roughly 13% two-session drop after the November 3 midterms was tied to a Texas governor-elect who campaigned on pausing new data-center construction, which bears on SpaceX's AI-infrastructure plans [20]. Bulls point to the Q3 beat, AI revenue above $7.5B [4], strong analyst support and a large net cash position. Bears point to extreme multiples, deeply negative FCF with large future funding needs, earnings boosted by non-operating items, and heavy pending supply. The evidence supports neither case decisively, and the reader should weigh these factors themselves.

Figures as of Nov 15, 2026 · 5 days ago

22 verified findings 30 cited sources
Now covering crypto

Crypto reports, same rigor

The same multi-source, adversarially-verified analysis — tuned for crypto: tokenomics, on-chain health, technicals, and regulatory risk.

HYPE logo
HYPE

Hyperliquid

Example report

Valuation and tokenomics present the central tension. HYPE trades near $84 with a circulating market cap of roughly $20.1 billion and an FDV of about $80 billion, because only 239.4 million of the 1 billion max supply (23.9%) is circulating, producing a ~4.0x FDV-to-market-cap ratio [4][6][7][10]. Against peer BNB, HYPE's circulating cap is about 22% of BNB's $91.3 billion while its FDV is about 88% of BNB's, underscoring a much larger locked-supply overhang [8]. Core contributors hold 23.80% of genesis supply and unlock at roughly 9.9 million HYPE per month through 2027, with the next tranche dated November 6, 2026 [13][15][17]; sources conflict on the size of that tranche, with one report describing it as trimmed to 180,000 HYPE (~$15.7M) from 9.92 million scheduled [12]. Offsetting this, the Assistance Fund routes 97-99% of protocol fees into open-market buybacks that have removed about 49.87 million HYPE (~5% of max supply) at a recent pace of roughly 591,000 HYPE per month, well below the monthly contributor unlock [17][20]. The fee base behind those buybacks is substantial: $84.78 million in 30-day fees and roughly $713 million in trailing-12-month revenue [9]. Staking yields about 2.24-2.37% with 7-day unstaking, and roughly 439 million HYPE is staked, a figure that exceeds circulating supply because vesting allocations can stake [14][19]. On network health and the regulatory picture, the evidence is mixed. DefiLlama reports Hyperliquid L1 TVL of about $2.54 billion by one measure and $8.07 billion by a broader one, and 24h active addresses of 19,111, but no consistent active-address trend series was available [16][21]. HIP-3 builder perps have scaled to 484 markets with cumulative volume above $548 billion, yet a single deployer, Trade.xyz, holds over 90% of HIP-3 open interest, and the core node code is not published as source [23][25]. Foundation-linked validators controlled about 48.9% of stake as of June 2026 [22]. The November 3 CFTC approval of U.S. equity perpetuals lifted HYPE about 2% and Hyperliquid has named Kraken parent Payward, via Bitnomial, as its planned first CFTC-regulated HIP-3 deployer, though that remains on testnet pending approval, Hyperliquid itself still blocks U.S. users, and Cboe, Citadel Securities and the Healthy Markets Association have sued to challenge the CFTC ruling [1][5]. Technically, HYPE sits slightly below its 50-day average but 20-25% above its 200-day average, with neutral RSI readings of roughly 41-55, about 14% below the $97.96 all-time high set September 23 [2][6][11]. Support clusters at $78.4 and the $75.7-$76 October low with deeper levels at $67.6 and $61.2, while resistance stacks at $85-$88, $92-$94.6 and $97.96 [3]. Near-term pressure includes $109 million of whale sales on October 31, a reported $224 million Paradigm unstake, and $612 million of leveraged longs clustered just below $86 [12]. Analysts are split: a potential head-and-shoulders targets $59-$62 if $76-$78 breaks, while a rebound scenario projects $112-$116; neither is confirmed [24]. Longer-term, HYPE is up roughly 99% over six months and 106-109% over twelve months, though aggregators disagree on exact figures [18].

Figures as of Nov 4, 2026 · 16 days ago

25 verified findings 35 cited sources
BTC logo
BTC

Bitcoin

Example report

Where valuation stands today: Bitcoin trades around $58,300–$58,600 with a market cap near $1.18 trillion [1], after falling roughly 20% in June 2026 (opening near $73,500, closing near $58,500) [5] and roughly 43.7% over the trailing 12 months [12] — well below the 2025 all-time high near $126K [11]. Unlike equities, BTC has no earnings-based valuation; its 'fundamentals' are supply/issuance, network security, and flows. The proximate drivers of the drawdown were record spot-ETF outflows (a ~$3.4B single-week record, the largest since the January 2024 launch, with ~$4.5B redeemed across June — the worst month on record, including a 13-day outflow streak of ~$4.4B) [4][6], a hawkish Fed repricing that pushed the 10-year Treasury yield up ~18bps to ~4.82% and rate cuts toward 2027 [10], and profit-taking as a ~34% two-month rally that peaked near $74,500 in late May reversed ~22% [9]. Geopolitical stress (the reported 103rd day of the U.S.-Israel–Iran conflict and an oil-price spike) added risk-off pressure, though on a single, low-confidence source [15].

Figures as of Jul 1, 2026 · 142 days ago

15 verified findings 24 cited sources
SOL logo
SOL

Solana

Example report

Valuation and tokenomics: As of 2026-07-01 SOL trades near $73 (aggregator band ~$72.69–$74.61) for a market cap of ~$42.7B and FDV of ~$46.3B, ranking #7 [1][4][5]. With ~580.9M of ~629.5M tokens circulating (~92.3%) and an uncapped, inflationary supply, the market-cap-to-FDV ratio sits near 0.92 — only ~8% overhang, and most future dilution comes from ongoing ~3.77% inflation (disinflating 15%/yr from an 8% start toward a 1.5% floor) rather than large unlock cliffs [3][6][7][9][15]. The FTX/Alameda estate's residual ~5M locked SOL is under ~1% of float, so the unlock overhang is modest [8]. About 67.9% of supply (~427M SOL) is staked at ~5.5–6.5% APY, and SOL's market cap is roughly 22% of Ethereum's ~$190.1B [2][3][22]. Note one same-source snapshot lists a slightly higher $43.4B cap / $47.0B FDV, illustrating intra-day aggregator variance [12]. Bull case (network health, catalysts, technicals): Solana posts strong usage — a record ~2.1M daily active addresses and ~238.5M daily transactions at the highest throughput among major L1s (~$0.00025/tx), SOL-denominated TVL at an all-time high above 80M SOL in Feb 2026, a record ~11,534 new developers, and 2,100+ active dApps [16][17][19]. Institutional access is the marquee catalyst: U.S. spot SOL ETFs launched ~Oct 2025 (BSOL, FSOL) with ~$1.3–1.45B cumulative inflows, Morgan Stanley filings in Jan 2026, and Alpenglow/Firedancer upgrades cited as supportive, with SEC deadlines mid-to-late 2026 [13][20]. Technically the posture is mildly bullish/neutral: spot sits fractionally above the 50-day (~$72.12) and 200-day (~$71.62) averages, RSI(14) reads a neutral ~52–62, and SOL is up ~50.3% over 12 months [5][11][21]. Bear case, key risks, and what would change the read: The core bear signal is weak value capture — of ~$10M daily ecosystem fees only ~$100k accrues to the protocol, and monthly Real Economic Value collapsed ~95% from ~$550M (Jan 2025) to ~$23.5M (Dec 2025), suggesting much 2025 activity was speculative [18]. USD DeFi TVL fell from ~$9B to ~$5.5–6B after the April 2026 Drift exploit, and SOL remains ~74.6% below its $293.31 ATH (Jan 2025) [11][17]. The proposed SIMD-0550 (not enacted) could accelerate disinflation and cut modeled staking yields to ~4.3% in year one and ~2.25% by year three, and ~600k SOL flowing to exchanges leaves holder-flow direction genuinely mixed against concurrent whale accumulation [14][24]; regulatory outcomes (CLARITY/GENIUS Act, pending SEC decisions) remain open [20]. On the balance point: a weekly close above $73.50 opens $75–$80, while losing $71.50 exposes $68, then $64 and the $60 June floor — with sustained ETF inflows vs. outflows the specific factor most likely to flip the balanced read [10][13][23].

Figures as of Jul 1, 2026 · 142 days ago

24 verified findings 29 cited sources
DOGE logo
DOGE

Dogecoin

Example report

Price/technical state: As of June 7, 2026, DOGE trades around $0.083-$0.085 with a market cap of roughly $13-14.3B (rank #10-11) and ~$0.68-0.76B in 24h volume. The picture is bearish in the near term. DOGE is down ~16% over 7 days and ~23-30% over 30 days, having broken a descending channel near June 4 amid a sector-wide memecoin selloff (BONK, PEPE, SHIB also fell). Six-month return is roughly -40% and the 12-month return is contested (~-52% to -63% on some trackers, though CoinGecko shows +54% on a 1y basis depending on the start date), reflecting how much DOGE has retraced from its late-2024/early-2025 highs. Price sits well below both its 50-day MA (~$0.10-0.11) and 200-day MA, a bearish alignment, and RSI(14) is near 30 (oversold). Near-term support clusters around $0.080-0.082 with resistance near $0.095-0.105. Bull case: DOGE retains deep liquidity, the strongest meme-coin brand, and is now nearly 4x Shiba Inu's market cap (~$13-14B vs ~$3.6B) with far higher turnover. In March 2026 the SEC and CFTC jointly classified DOGE as a digital commodity (one of 16 named assets), removing the main legal barrier to spot ETFs and shifting oversight toward the lighter-touch CFTC. Multiple U.S. spot/derivative ETF wrappers now exist (REX-Osprey DOJE since Sept 2025; 21Shares TDOG on Nasdaq since Jan 2026, 0.50% fee; Grayscale and Bitwise products auto-launched in late 2025), giving regulated access. Payments adoption has incrementally improved: Tesla reinstated DOGE for merchandise/Cybertruck accessories in 2026, the Dallas Mavericks accept it, and Musk's X Money launch is a sentiment driver. Whale wallets reached multi-year/all-time highs in 2026 (e.g., ~108B+ DOGE held by the largest cohort per Santiment), framed by some as professional accumulation. Tokenomics are disinflationary: a FIXED 5B DOGE/year tail emission (10,000 DOGE/block, ~1-min blocks) means the inflation rate keeps falling (~3.2% now, toward ~2% by ~2040), and ~70%+ of security comes free via merged mining with Litecoin. Bear case/risks: DOGE has no max supply and perpetual issuance, so demand must absorb ~5B new coins every year indefinitely. ETF demand has been tiny: combined U.S. DOGE-ETF AUM was only ~$14.7M as of mid-May 2026 (DOJE ~$18-20M, TDOG ~$4M), a fraction of BTC/ETH ETF scale, and several sessions in late May 2026 saw zero daily flows. Ownership is extremely concentrated: the top 100 addresses hold ~66-67% of supply, the top 10 ~45-60%, and the single largest wallet (Robinhood's cold wallet) holds ~27.2B DOGE, ~18% of supply (the famous ~28-30B address; it is custodial user funds, not one whale). On-chain usage is modest relative to market cap (~30,000 active addresses/day, ~22,000 tx/day, ~$110M transferred), with most volume speculative; developer activity and native utility remain low versus Ethereum/Solana. DOGE stays heavily dependent on Musk/X headlines and broad memecoin sentiment, making it prone to sharp reversals. This report is informational only and is not a buy or sell recommendation.

Figures as of Jun 7, 2026 · 166 days ago

18 verified findings 41 cited sources

How it works

Every report runs through the same 4-phase pipeline. No shortcuts.

1

Profile

We scope the company — sector, business model, and what actually moves the stock — so the research targets what matters.

2

Research

Five parallel agents cover fundamentals, analyst targets, technicals, risks, and the bear case, each with live web search.

3

Verify

Every finding faces two skeptical verifiers that try to refute it with independent searches. Unverified claims get dropped.

4

Synthesize

What survives is synthesized into a balanced bull-vs-bear narrative — every claim traceable to a real source URL.

Same-day repeats are served instantly from cache; older reports get a lightweight delta refresh.

Pricing

Same pipeline, same quality across every tier. You're paying for how fast you see it.

Saver

Patient research at the lowest price

$15/ report

48 hour delivery

  • Full multi-source pipeline
  • 5 angle research + live web search
  • Adversarial fact verification
  • Real cited sources
  • Delivered in 48 hours
Most popular

Standard

The right balance of speed and price

$30/ report

24 hour delivery

  • Full multi-source pipeline
  • Same research depth, every tier
  • Adversarial fact verification
  • Real cited sources
  • Delivered in 24 hours

Priority

Premium access for time-sensitive decisions

$100/ report

4 hour delivery

  • Full multi-source pipeline
  • Same research depth, every tier
  • Adversarial fact verification
  • Real cited sources
  • Delivered in 4 hours

Repeat requests on the same ticker the same day are served from the latest report.

Frequently asked questions

Everything you need to know before your first report.

Is this investment advice?

No. Every report is for informational purposes only and makes no buy, sell, or hold recommendation. Do your own research and consult a licensed advisor before investing.

How fast will I get my report?

It depends on the tier you pick: Priority delivers within 4 hours, Standard within 24 hours, and Saver within 48 hours. The analysis is identical across tiers — you're only paying for speed.

What's actually different between the tiers?

Nothing about the research itself. Every tier runs the same four-phase pipeline with the same depth, verification, and citations. The only difference is how soon the report unlocks.

How is the analysis generated?

Five research agents cover fundamentals, analyst targets, technicals, risks, and the bear case using live web search. Each finding is then challenged by skeptical verifiers, and only claims that survive are synthesized into the final report — every one traceable to a real source URL.

Do I pay again for the same stock?

A same-day repeat request on the same ticker is served from the latest report. If meaningful time has passed, we run a lightweight delta refresh instead of a full report.

What happens if a report fails?

You're never charged for a report we can't deliver. Any payment for a failed report is automatically refunded.

Intuit's fiscal Q1 2027 beat estimates, but the outlook behind it got worse. Revenue was $4.354B, up 12% from $3.885B, against roughly $4.31B expected. GAAP diluted EPS was $2.59, up 63%, and non-GAAP EPS was $2.91, up 56%. The beat was $0.21 against a $2.70 consensus or $0.45 against $2.46, depending on the benchmark…

— Intuit Inc (INTU) analysis, generated Nov 20, 2026 · today. Browse full example reports →